SCHEDULE: NEA's Monte Rosa Therapeutics Stake Dips to 9.6%

New Enterprise Associates 17, L.P. and its affiliates reported a decrease in their beneficial ownership of Monte Rosa Therapeutics, Inc. common stock to 9.6% due to an increase in the issuer's outstanding shares.

Summary

• New Enterprise Associates 17, L.P. (NEA 17), NEA Partners 17, L.P., NEA 17 GP, LLC, and several individual managers (collectively, "Reporting Persons") filed an Amendment No. 3 to their Schedule 13D.
• The amendment reports a decrease in the beneficial ownership of Monte Rosa Therapeutics, Inc. (Issuer) Common Stock by more than 1%.
• This decrease in percentage ownership is attributed to an increase in the number of Common Stock outstanding.
• NEA 17, NEA Partners 17, NEA 17 GP, LLC, and most individual managers now beneficially own 7,692,298 shares, representing 9.6% of the class.
• Ali Behbahani beneficially owns 7,797,030 shares (including options to purchase 104,732 shares), representing 9.7% of the class.
• The percentage calculations are based on 80,015,667 shares of Common Stock outstanding as of March 2, 2026, as reported in the Issuer's Form 10-K filed on March 17, 2026.
• The Reporting Persons acquired shares for investment purposes and may dispose of or acquire additional shares depending on market conditions and evaluation of the Issuer.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative for the reporting entity's relative influence due to dilution, though it's a routine disclosure for a Schedule 13D/A.

Negatives

• The beneficial ownership percentage of the Reporting Persons decreased by more than 1%.
• The decrease in percentage ownership is due to an increase in the number of Monte Rosa Therapeutics, Inc. Common Stock outstanding, indicating dilution for existing shareholders.

Future Outlook

Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, NEA 17 and the other Reporting Persons may dispose of or acquire additional shares of the Issuer.

Industry Context

StockSavvy.ai notes that a decrease in a significant investor's percentage ownership, particularly when attributed to an increase in outstanding shares, often signals a capital raise or other dilutive event by the issuer. This can impact investor sentiment regarding the company's financing strategy and the relative value of existing holdings.

Stakeholder Impact

• Shareholders: Existing shareholders of Monte Rosa Therapeutics, Inc. experienced dilution due to the increase in outstanding shares, which reduced the percentage ownership of the Reporting Persons.

Next Steps

• Reporting Persons may dispose of or acquire additional shares of the Issuer depending on market conditions and evaluation of the Issuer's business and prospects.

Key Dates

Recommendation

This filing primarily reports a change in beneficial ownership percentage due to dilution, not a change in the reporting entity's investment thesis or the underlying performance of Monte Rosa Therapeutics. While dilution is generally a negative, the filing itself does not provide enough information to warrant a 'sell' or 'buy' recommendation without further analysis of Monte Rosa's operational and financial performance. Investors should hold and monitor for further developments.

Keywords

Monte Rosa Therapeutics, New Enterprise Associates, NEA 17, Schedule 13D, beneficial ownership, common stock, dilution, SEC filing, investment, biotechnology, pharmaceuticals